ArticleAsian Pacific journal of cancer prevention : APJCP2025
Is GATA3 Useful for Differentiating between Classical Hodgkin Lymphoma and Nodular Lymphocyte-Predominant Hodgkin lymphoma? A Two-Center Study in Tehran, Iran during 2016 to 2022.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHodgkin's lymphoma (HL) has two main types; classic HL and nodular lymphocyte predominant HL (NLPHL) which should be differentiated due to the differences in treatment options and prognosis. While a reliable immune panel exists for the diagnosis of Hodgkin Lymphoma, there are instances where certain cases may not align perfectly with established categories. Hence, further research is required to discover more accurate and specific markers. The current study aimed to evaluate GATA3 immunohistochemical expression pattern in classic HL and NLPHL.
methodsThis retrospective cross-sectional study was conducted on patients with HL diagnosis who were referred to the Imam Khomeini and Dr. Shariati Hospitals, Tehran, Iran from 2016 to 2022. Clinical and demographic data were collected from medical records, while immunohistochemical staining and evaluation were performed on paraffin-embedded tissue blocks. GATA3 expression was considered positive if nuclear staining was seen in neoplastic cells. The staining intensity was graded as weak (+1), medium (+2) and strong (+3).
resultOut of the 60 samples analyzed (30 classic HL and 30 NLPHL samples), the average age of NLPHL patients (36.7 ± 16.44) was significantly higher compared to classic HL patients (28.6 ± 13.88, p=0.031). GATA3 nuclear expression was present in 63.3% of classic HL samples, while no expression was observed in NLPHL samples. Different levels of staining weak, medium, and strong were found in 20%, 26.7%, and 16.7% of the samples, respectively. There was no correlation between GATA3 expression intensity and overall expression with gender, age group, or histologic subtypes (p>0.05).
conclusionDifferentiating between classic HL and NLPHL can be aided by the presence of GATA3 expression, which favors cHL; however, its absence does not provide a diagnostic tool for classification of HL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.